JP2021184731A5 - - Google Patents

Download PDF

Info

Publication number
JP2021184731A5
JP2021184731A5 JP2021128846A JP2021128846A JP2021184731A5 JP 2021184731 A5 JP2021184731 A5 JP 2021184731A5 JP 2021128846 A JP2021128846 A JP 2021128846A JP 2021128846 A JP2021128846 A JP 2021128846A JP 2021184731 A5 JP2021184731 A5 JP 2021184731A5
Authority
JP
Japan
Prior art keywords
seq
antigen
antibody
binding
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021128846A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021184731A (ja
Filing date
Publication date
Priority claimed from EP15305078.6A external-priority patent/EP2955196A1/en
Application filed filed Critical
Publication of JP2021184731A publication Critical patent/JP2021184731A/ja
Publication of JP2021184731A5 publication Critical patent/JP2021184731A5/ja
Pending legal-status Critical Current

Links

JP2021128846A 2014-06-10 2021-08-05 Cd127に対する抗体 Pending JP2021184731A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462010117P 2014-06-10 2014-06-10
US62/010,117 2014-06-10
EP15305078.6 2015-01-23
EP15305078.6A EP2955196A1 (en) 2014-06-10 2015-01-23 Antibodies directed against CD127
JP2017517406A JP7324565B2 (ja) 2014-06-10 2015-06-10 Cd127に対する抗体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017517406A Division JP7324565B2 (ja) 2014-06-10 2015-06-10 Cd127に対する抗体

Publications (2)

Publication Number Publication Date
JP2021184731A JP2021184731A (ja) 2021-12-09
JP2021184731A5 true JP2021184731A5 (enExample) 2022-03-03

Family

ID=52434718

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017517406A Active JP7324565B2 (ja) 2014-06-10 2015-06-10 Cd127に対する抗体
JP2021128846A Pending JP2021184731A (ja) 2014-06-10 2021-08-05 Cd127に対する抗体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017517406A Active JP7324565B2 (ja) 2014-06-10 2015-06-10 Cd127に対する抗体

Country Status (26)

Country Link
US (3) US10428152B2 (enExample)
EP (2) EP2955196A1 (enExample)
JP (2) JP7324565B2 (enExample)
KR (1) KR102612930B1 (enExample)
CN (1) CN106715471B (enExample)
AP (1) AP2016009599A0 (enExample)
AU (1) AU2015273532C1 (enExample)
BR (1) BR112016028755B1 (enExample)
CA (1) CA2950823A1 (enExample)
CL (1) CL2016003172A1 (enExample)
CR (1) CR20160576A (enExample)
EA (1) EA039303B1 (enExample)
HK (1) HK1231487A1 (enExample)
IL (1) IL249449B (enExample)
MA (1) MA40202A (enExample)
MX (1) MX376066B (enExample)
MY (1) MY190889A (enExample)
NZ (1) NZ726932A (enExample)
PE (1) PE20170324A1 (enExample)
PH (1) PH12016502445A1 (enExample)
RU (1) RU2734076C2 (enExample)
SA (1) SA516380455B1 (enExample)
SG (1) SG11201610036PA (enExample)
TN (1) TN2016000528A1 (enExample)
UA (1) UA125366C2 (enExample)
WO (1) WO2015189302A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013124474A2 (en) 2012-02-23 2013-08-29 Stage Cell Therapeutics Gmbh Chromatographic isolation of cells and other complex biological materials
EP2955196A1 (en) * 2014-06-10 2015-12-16 Effimune Antibodies directed against CD127
WO2016156468A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptides
CN107427577A (zh) 2015-03-31 2017-12-01 韦斯夸尔德有限公司 具有蛋白酶可切割接头的肽构建体
IL258844B2 (en) 2015-10-22 2024-03-01 Juno Therapeutics Gmbh Methods for culturing cells and kits and apparatus for same
WO2017125578A1 (en) 2016-01-21 2017-07-27 Vhsquared Limited Polypeptides
RS59223B1 (sr) * 2016-02-29 2019-10-31 Ose Immunotherapeutics Ne-antagonistička antitela usmerena protiv alfa lanca ekstracelularnog domena il7 receptora i njihova upotreba u lečenju kancera
PE20191152A1 (es) 2016-12-09 2019-09-05 Ose Immunotherapeutics Anticuerpos y polipeptidos dirigidos contra cd127
EP3676292A1 (en) * 2017-08-29 2020-07-08 OSE Immunotherapeutics Method and preparation for sorting out t effector cells using anti-cd127 antibodies for applications in cell therapy
CN110117325B (zh) * 2018-03-09 2023-06-20 重庆市畜牧科学院 一种猪cd127多肽及其编码基因和应用
KR20230128134A (ko) 2019-01-22 2023-09-01 브리스톨-마이어스 스큅 컴퍼니 Il-7r 알파 서브유닛에 대한 항체 및 이의 용도
IL288024B2 (en) 2019-05-14 2025-12-01 Provention Bio Inc Methods and compositions for preventing type
MX2021015762A (es) 2019-06-21 2022-04-18 Sorriso Pharmaceuticals Inc Composiciones.
MX2021015761A (es) 2019-06-21 2022-04-18 Sorriso Pharmaceuticals Inc Polipeptidos.
AU2020296979A1 (en) 2019-06-21 2022-02-24 Sorriso Pharmaceuticals, Inc. Polypeptides
CN110894237B (zh) * 2019-12-05 2021-08-03 山东省分析测试中心 抗cd127的抗体、分泌该抗体的细胞株及其制备方法和应用
EP4142777A4 (en) * 2020-04-27 2024-06-12 Memorial Sloan-Kettering Cancer Center CHIMERIC ANTIGEN RECEPTORS DIRECTED TO CD127 AND USE THEREOF
US12006366B2 (en) 2020-06-11 2024-06-11 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
US20220389104A1 (en) * 2021-05-28 2022-12-08 Ose Immunotherapeutics Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent
CA3250546A1 (en) 2022-05-30 2023-12-07 Ose Immunotherapeutics IL7R MODULATOR ACTIVITY BIOMARKERS
CN115925955B (zh) * 2022-12-30 2025-09-26 浙江正熙生物技术有限公司 一种抗cd127抗体及其制备方法和应用
EP4646274A1 (en) 2023-01-06 2025-11-12 Twain Therapeutics Pte. Ltd. Antigen-binding molecules
EP4455308A1 (en) 2023-04-24 2024-10-30 Les Laboratoires Servier Il-7r gene signatures
CN121666232A (zh) 2023-05-31 2026-03-13 开普斯坦治疗公司 脂质纳米颗粒制剂和组合物
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025089399A1 (ja) * 2023-10-26 2025-05-01 国立研究開発法人国立がん研究センター インターロイキン7受容体(il-7r)に対する抗体および当該抗体を含む抗体薬物コンジュゲート(adc)
WO2025179294A2 (en) 2024-02-22 2025-08-28 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025202213A1 (en) 2024-03-26 2025-10-02 Institut National de la Santé et de la Recherche Médicale Lipid nanoparticle loaded with antitumoral agent and functionnalized to target immosuppressive cells
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
CN118638236B (zh) * 2024-07-09 2025-03-14 武汉爱博泰克生物科技有限公司 抗人cd127蛋白的抗体、抗体偶联物及其应用
WO2026022216A1 (en) 2024-07-23 2026-01-29 Ose Immunotherapeutics Uses of anti-cd127 antibodies in the treatment of inflammatory bowel diseases
WO2026033132A1 (en) 2024-08-09 2026-02-12 Twain Therapeutics Pte. Ltd. Antigen-binding molecules

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
AU2007266450A1 (en) 2006-05-31 2007-12-06 The Regents Of The University Of California CD127 expression inversely correlates with FoxP3 and suppressive function of CD4+ Tregs
EP1930342B1 (en) 2006-12-04 2012-01-25 Institut Pasteur OB-fold used as scaffold for engineering new specific binders
UY32038A (es) 2008-08-08 2010-03-26 Glaxo Wellcome Mfg Pte Ltd Inmunoblobulinas anti-cd127 y sus usos
WO2010085643A1 (en) 2009-01-22 2010-07-29 University Of Miami Targeting il-7 signaling as a therapy for multiple sclerosis and other il-7 signaling dependent disorders
US8940303B2 (en) * 2010-01-28 2015-01-27 Glaxo Group Limited CD127 binding proteins
US8298535B2 (en) 2010-02-24 2012-10-30 Rinat Neuroscience Corp. Anti-IL-7 receptor antibodies
EP2583980A1 (en) 2011-10-19 2013-04-24 Effimune Antibodies directed against the alpha chain of IL7 receptor - their use for the preparation of drug candidates
EP2955196A1 (en) * 2014-06-10 2015-12-16 Effimune Antibodies directed against CD127
RS59223B1 (sr) 2016-02-29 2019-10-31 Ose Immunotherapeutics Ne-antagonistička antitela usmerena protiv alfa lanca ekstracelularnog domena il7 receptora i njihova upotreba u lečenju kancera

Similar Documents

Publication Publication Date Title
JP2021184731A5 (enExample)
KR102821932B1 (ko) 항-ccr8 항체 및 이의 용도
JP7325936B2 (ja) 改善された貯蔵及び投与のための、二重特異性抗体構築物を含む医薬組成物
JP2017522903A5 (enExample)
JP7011574B2 (ja) Flt3及びcd3に対する抗体構築物
JP6879998B2 (ja) Cd70及びcd3に対する抗体構築物
JP6726168B2 (ja) Cdh19およびcd3に対する抗体コンストラクト
JP6907124B2 (ja) Cdh3及びcd3に対する二重特異性抗体構築物
JP6305919B2 (ja) Mcamアンタゴニスト及び治療の方法
RU2016151265A (ru) Антитела, направленные на cd127
KR20240118898A (ko) Bcma 및 cd3 이중특이성 t 세포 맞물림 항체 작제물
SA515360253B1 (ar) أجسام مضادة مُميزة لألفا سينوكلين
TW201708261A (zh) Dll3及cd3抗體構築體
KR20160065981A (ko) 신경퇴행성 장애의 치료를 위한 세마포린-4d 결합 분자의 용도
CN110396129A (zh) 人源化cd19抗原结合单链抗体及其嵌合抗原受体、免疫细胞和应用
TW201922773A (zh) 雙特異性抗cd307e及抗bcma嵌合抗原受體之製造方法及用途
AU2014305658A1 (en) An antibody therapy for amyloid beta disease
CA2986210C (en) Novel anti-human ngf antibody fab fragment
KR20240006586A (ko) Rankl 및 ngf에 특이적으로 결합하는 항원 결합 분자, 및 이의 의학적 용도
US11702470B2 (en) Use of CXCL13 binding molecules to promote peripheral nerve regeneration
JP2024526154A (ja) フィブロネクチン-インテグリン相互作用及びシグナル伝達を検出及び調節するための組成物及び方法
WO2025171411A1 (en) Compositions and methods related to modulating macrophage migration inhibitory factor (mif)-cd74 signaling and related treatments for neuroinflammatory conditions
KR20230144870A (ko) Mincle 억제제를 포함하는 신경병성 통증 치료용 약학 조성물
WO2026056681A1 (zh) 靶向人cd33的人源化抗体及其应用
EA046884B1 (ru) Фармацевтическая композиция, содержащая конструкции на основе биспецифического антитела, обеспечивающая улучшенное хранение и введение